Aadi bioscience to participate in jefferies london healthcare conference

Los angeles , nov. 6, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, announced today participation in the jefferies london healthcare conference, taking place november 14-16, 2023, in london. dave lennon, ph.d.
AADI Ratings Summary
AADI Quant Ranking